Compass Therapeutics (CMPX) Research & Development (2019 - 2026)

Compass Therapeutics has disclosed Research & Development across 8 years of filings, most recently posting $13.4 million for Q1 2026.

• Research & Development for Q1 2026 came in at $13.4 million, up 2.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $56.3 million (up 22.72% YoY), and the FY2025 annual result was $56.0 million, up 32.18% from the prior year.
• Research & Development came in at $13.4 million for Q1 2026 at Compass Therapeutics, down from $13.7 million in the prior quarter.
• In the past five years, Research & Development ranged from a high of $16.4 million in Q2 2025 to a low of $4.4 million in Q1 2022.
• The 5-year median for Research & Development is $10.2 million (2023), against an average of $10.6 million.
• Across the five-year window, Research & Development soared 210.43% in 2022 and retreated 9.8% in 2023, its largest moves.
• Compass Therapeutics' Research & Development stood at $9.9 million in 2022, then grew by 25.16% to $12.4 million in 2023, then grew by 4.93% to $13.0 million in 2024, then gained by 4.86% to $13.7 million in 2025, then retreated by 2.06% to $13.4 million in 2026.
• The last three Research & Development figures came in at $13.4 million (Q1 2026), $13.7 million (Q4 2025), and $12.8 million (Q3 2025), per Business Quant data.